D. Hanekamp

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Markus G. Manz, Bob Löwenberg, Carlos Graux, 2018, The New England journal of medicine.

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

V. V. D. van der Velden, M. Jongen‐Lavrencic, T. Pabst, 2018, Leukemia.

CD45RA, a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia

G. Schuurhuis, G. Ossenkoppele, J. Cloos, 2016, British journal of haematology.

Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.

G. Ossenkoppele, J. Cloos, A. A. van de Loosdrecht, 2019, Pathology.

Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.

J. Janssen, G. Ossenkoppele, J. Cloos, 2020, Blood.

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML

G. Schuurhuis, G. Ossenkoppele, J. Cloos, 2021, Cancers.

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

G. Schuurhuis, J. Janssen, G. Ossenkoppele, 2018, Journal of visualized experiments : JoVE.

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

M. Jongen‐Lavrencic, G. Ossenkoppele, M. Manz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting

P. Vyas, V. V. D. van der Velden, N. Khan, 2020, British journal of haematology.

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

P. Valk, D. Hanekamp, A. A. Al Hinai, 2016, Cancers.